Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver TransplantationGlobeNewsWire · Sep 9, 2026
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudyGlobeNewsWire · Sep 8, 2026
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer StudyBenzinga · Sep 2, 2026
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross ProceedsGlobeNewsWire · Sep 2, 2026
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudyGlobeNewsWire · Sep 2, 2026
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic CancerGlobeNewsWire · Aug 17, 2026Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 8, 2026 | -$0.33 | -$1.24 | Miss |
| Mar 26, 2026 | -$27.00 | -$5.97 | Beat |
| Aug 28, 2025 | -$4.15 | -$0.00 | Beat |
| Apr 14, 2025 | -$0.10 | -$0.10 | Beat |
| Mar 27, 2025 | -$0.24 | -$0.00 | Beat |
| Jan 2, 2025 | -$0.27 | -$0.27 | Beat |